Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: A meta-analysis

Journal of Hypertension

Volumn 26, Issue 7, 2008, Pages 1282-1289

  Reboldi, Gianpaolo ^a   Angeli, Fabio ^b   Cavallini, Claudio ^b   Gentile, Giorgio ^a   Mancia, Giuseppe ^c   Verdecchia, Paolo ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Hypertension; Meta analysis; Mortality; Myocardial infarction; Prevention; Prognosis; stroke; Therapy

Indexed keywords

CAPTOPRIL; ENALAPRIL; LOSARTAN; RAMIPRIL; TELMISARTAN; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; FOLLOW UP; GENETIC HETEROGENEITY; HEART FAILURE; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STROKE; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE;

EID: 52149090673     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328306ebe2     Document Type: Article

References (41)

1. Wong J, Patel RA, Kowey PR. The clinical use of angiotensin-converting enzyme inhibitors. Prog Cardiovasc Dis 2004; 47:116-130.
2. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
3. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21:1055-1076.
4. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25:951 -958.
5. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46:386-392.
6. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 1997; 349:747-752.
7. Pitt B, Poole-Wilson PA, Segal R. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: the losartan heart failure survival study ELITE II. Lancet 2000; 355:1582-1587.
8. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin ii antagonist losartan. Lancet 2002; 360:752 - 760.
9. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Keber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1904.
10. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al., Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin- receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952-1961; Erratum in: N Engl J Med 2005; 352:1731.
11. Unger T, Stoppelhaar M. Rationale for double renin-angiotensin- aldosterone system blockade. Am J Cardiol 2007; 100 (3A):25J-31J.
12. Bennett MR, Macdonald K, Chan S, Boyle JJ, Weissberg PL. Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques. Circ Res 1998; 82:704-712.
13. Diep QN, Li JS, Schiffrin EL. In vivo study of AT1 and AT2 angiotensin receptors in apoptosis in rat blood vessels. Hypertension 1999; 34:617-624.
14. Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004; 109:8-13.
15. Vacanti L. Could angiotensin receptor blockers and activation of AT2 induce plaque rupture, ratherthan repair? BMJ 2004; Rapid Response (23 December 2004).
16. Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, Timm M, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; 19:617-619.
17. Fournier A, Achard JM, Boutitie F, Mazouz H, Mansour J, Oprisiu R, et al. Is the angiotensin II type 2 receptor cerebroprotective? Curr Hypertens Rep 2004; 6:182-189.
18. Verma S, Strauss M. Angiotensin receptor blocker and myocardial infarction. BMJ 2004; 329:1248-1249.
19. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
20. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36:1218-1226.
21. Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005; 26:2381 -2386.
22. Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. JHypertens 2005; 23:2113-2118.
23. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unravelling the ARB-MI paradox. Circulation 2006; 114:838 -854.
24. Tsuyuki RT, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 2006; 114:855-860.
25. Boutitie F, Oprisiu R, Achard JM, Mazouz H, Wang J, Messerli FH, et al. Does a change in angiotensin II formation caused byantihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II. J Hypertens 2007; 25:1543-1553.
26. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
27. Haynes RB, Wilczynski N, McKibbon KA, Walker CJ, Sinclair JC. Developing optimal search strategies for detecting clinically sound studies in MEDLINE. J Am Med Inform Assoc 1994; 1:447-458.
28. McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis ofthe Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006; 47:726-733.
29. Whitehead A. Estimating the treatment difference in an individual trial. In: Meta-analysis of Controlled Clinical Trials. Chichester: John Wiley & Sons Ltd. 2002. pp. 23-50.
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560.
31. Tobias A. Assessing the influences of a single study in meta-analysis. Stata Tech Bull 1999; 47:15-17.
32. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, etal. Assessing the qualityofreports ofrandomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1 -12.
33. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004; 110:843-848.
34. Krikov M, Thone-Reineke C, Müller S, Villringer A, Unger T. Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. J Hypertens 2008; 26:544-552.
35. Dai W, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999; 30:2391 -2399.
36. Zhang H, Thijs L, Staessen JA. Blood pressure lowering for primary and secondary prevention of stroke. Hypertension 2006; 48:187 -195.
37. Verma S, Mamdani M, Al-Omran M, Melo M, Rouleau JL. Angiotensin receptor blockers vs. angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: a population-based cohort study (UMPIRE study results). J Am Soc Hypertens 2007; 1:286- 294.
38. Delea TE, Taneja C, Moynahan A, Thomas SK, Frech-Tamas F, Oster G. Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension. Am J Health Syst Pharm 2007; 64:1187-1196.
39. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
40. Zhou M, Offer A, Yang G, Smith M, Hui G, Whitlock G, et al. Body mass index, blood pressure, and mortality from stroke: a nationally representative prospective study of 212 000 Chinese men. Stroke 2008; 39:753-759.
41. Vickrey BG, Rector TS, Wickstrom SL, Guzy PM, Sloss EM, Gorelick PB, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002; 33:901 -906.